Publications by authors named "J Schaeverbeke"
Introduction: Blood-based glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) have shown promising prognostic potential in Alzheimer's disease (AD), but their applicability in clinical settings where comorbidities are prevalent remains uncertain.
Methods: Simoa assays quantified GFAP, NfL, and pTau181 in retrospectively retrieved prediagnostic serum samples from 102 AD patients and 21 non-AD controls.
Results: Higher serum GFAP levels predicted earlier clinical presentation and faster subsequent Mini-Mental State Examination decline in AD patients.
Article Synopsis
- Blood-derived DNA methylation shows potential for early detection of dementia risk, linking biological factors with lifestyle and environmental influences.
- A multivariate methylation risk score (MMRS) was developed, predicting mild cognitive impairment independently of age and sex, alongside significant future risk of cognitive decline in Alzheimer’s and Parkinson’s diseases.
- The study highlights the integration of machine learning and omics data to enhance dementia risk prediction at the population level.
Article Synopsis
- The study examined DNA methylation patterns in blood samples related to 15 key biomarkers of Alzheimer's disease, focusing on neuroinflammation and neurodegeneration effects.
- Using 885 samples from the EMIF-AD study, researchers identified significant differential methylation connected to CSF levels of YKL-40 and neurofilament light chain (NfL).
- Findings suggest a link between YKL-40 DNA methylation and genetic variants, with implications for understanding how DNA methylation influences protein levels relevant to Alzheimer's disease.
The dynamic phase of preclinical Alzheimer's disease, as characterized by accumulating cortical amyloid-β, is a window of opportunity for amyloid-β-lowering therapies to have greater efficacy. Biomarkers that accurately predict amyloid-β accumulation may be of critical importance for participant inclusion in secondary prevention trials and thus enhance development of early Alzheimer's disease therapies. We compared the abilities of baseline plasma pTau181, pTau217 and amyloid-β PET load to predict future amyloid-β accumulation in asymptomatic elderly.
View Article and Find Full Text PDF